StockNews.com Lowers Integra LifeSciences (NASDAQ:IART) to Hold

Integra LifeSciences (NASDAQ:IART - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday.

A number of other equities research analysts have also weighed in on the stock. Truist Financial reduced their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating on the stock in a report on Friday, March 1st. JMP Securities reduced their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating on the stock in a report on Thursday, February 29th. Finally, Citigroup raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 target price on the stock in a report on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $44.89.

Integra LifeSciences Price Performance

IART stock traded down $0.07 during trading on Tuesday, reaching $29.17. 650,226 shares of the company were exchanged, compared to its average volume of 702,239. The company has a 50-day moving average of $35.02 and a two-hundred day moving average of $38.71. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of 35.14, a P/E/G ratio of 0.85 and a beta of 1.12. Integra LifeSciences has a twelve month low of $27.18 and a twelve month high of $56.21. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.94 earnings per share. As a group, equities analysts predict that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Signaturefd LLC raised its holdings in shares of Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company's stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Hexagon Capital Partners LLC raised its holdings in shares of Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 370 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Integra LifeSciences in the third quarter valued at about $47,000. Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences in the first quarter valued at about $63,000. Finally, Covestor Ltd grew its position in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company's stock valued at $78,000 after buying an additional 921 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.